Incyte (INCY) said Wednesday the European Commission has approved Opzelura cream to treat moderate atopic dermatitis.
The approval covers adult patients for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or inappropriate, the company said.
This is the the second indication in the EU for Opzelura, which was previously cleared to treat non-segmental vitiligo with facial involvement, Incyte said.
Price: 129.06, Change: -0.88, Percent Change: -0.67
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments